Abstract: An electronic device may include a lenticular display. The lenticular display may have a lenticular lens film formed over an array of pixels. The display may have a number of independently controllable viewing zones. Each viewing zone displays a respective two-dimensional image. Each eye of the viewer may receive a different one of the two-dimensional images, resulting in a perceived three-dimensional image. The electronic device may include display pipeline circuitry that generates and processes content to be displayed on the lenticular display. Content generating circuitry may generate content that includes a plurality of two-dimensional images, each two-dimensional image corresponding to a respective viewing zone. Pixel mapping circuitry may be used to map the two-dimensional images to the array of pixels in the lenticular display. The array of pixels may have a diagonal layout. An offset map may be used by the pixel mapping circuitry to account for the diagonal layout.

Abstract: An electronic device may include a lenticular display. The lenticular display may have a lenticular lens film formed over an array of pixels. A plurality of lenticular lenses may extend across the length of the display. The lenticular lenses may be configured to enable stereoscopic viewing of the display such that a viewer perceives three-dimensional images. The display may have a number of independently controllable viewing zones. The viewer may be particularly susceptible to artifacts caused by crosstalk at the edge viewing zones within the primary field of view of the display. Certain types of content may also be more vulnerable to crosstalk than other types of content. Therefore, to mitigate crosstalk artifacts, the pixel value for each pixel may be adjusted based on the viewing zone of the respective pixel and content information (such as texture information or brightness information) associated with the respective pixel.

Abstract: An aqueous formulation includes a PEDF-derived short peptide (PDSP) having the sequence of one of SEQ ID NO: 1, 2, 3, 5, 6, 8, or 9; histidine having a concentration of 1 mM-100 mM; and an antioxidant and optionally a non-ionic tonicity agent. The pH value is around 5-9. The antioxidant is nicotinamide, which is at a concentration of 50 mM-1000 mM. The non-ionic tonicity agent is sorbitol, which is at a concentration of 0 mM-500 mM. A concentration of the PDSP is 0.01%-1% w/v.

Abstract: A pharmaceutical composition for boosting an immune response contains TREM-like transcript-1 (TREML1) extracellular domain (ECD) or stalk polypeptide. The TREML1 ECD or stalk polypeptide is derived from human or mouse TREML1. The pharmaceutical composition further contains an antigen as a vaccine, wherein the TREML1 ECD or stalk polypeptide functions as an adjuvant or immune booster.

Abstract: A hepatitis B virus (HBV) vaccine includes an HBV core antigen (HBcAg) and/or HBV surface antigen (HBsAg) formulated in nanocomplexes. The nanocomplexes contain chitosan and ?-PGA. These nanocomplexes containing HBc/sAg, chitosan, and ?-PGA can induce more balanced T helper cells (Th1 and Th2) polarization than can a conventional vaccine with an alum adjuvant. HBc/s-NC of the invention can elicit high levels of antibodies against HBsAg, a rapid elimination of HBsAg, and a slow decrease of HBeAg, indicating a phenomenon of HBsAg seroconversion. Thus, HBc/s-NC can overcome immune tolerance caused by chronic HBV infection to re-establish host immunity leading a functional cure.

Abstract: A pharmaceutical composition for use in treating hepatitis B virus (HBV) infection includes an effective amount of an antibody against CD11b or a binding fragment thereof. A method for treating hepatitis B virus infection includes administering to a subject in need thereof an antibody against CD11b. Anti-CD11b antibody binding to CD11b may trigger immunostimulatory responses, as evidenced by the following observations: increased surface expression of MHC II and CD86 in CD11b+ peripheral blood mononuclear cells (PBMCs); suppressed level of hepatitis B surface antigen (HBsAg) and HBV DNA in the blood; and accelerated clearance of HBV from liver.

Abstract: The present invention relates to methods for modulating immune response based on binding I-domain of CD11b on the tumor associated myeloid cells (TAMCs) in the tumor microenvironment. Particularly, binding to I-domain of CD11b with anti-CD11b-I-domain antibody triggers immunostimulatory environment that have one or more of the following effects in the tumor microenvironment: increase the inflammatory cytokine in the tumor microenvironment, decrease the population of IDO+ myeloid suppresser cells, up-regulate M1 marker over M2 marker on the tumor associated macrophage, increase M1:M2 tumor associated macrophage ratio, promote differentiation of dendritic cells (DC), nature killer dendritic cells (NKDC), and plasmacytoid dendritic cells (pDC), increase population of 4?1BB+PD?1+ neoantigen specific CD8 T cells. Converting cold (non-inflamed) to hot (inflamed) tumor by binding to I-domain of CD11b with anti-CD11b-I-domain antibody allows enhanced effectiveness of immune response modulator.

Abstract: A liquid isotope delivery system includes a pressure-controlling unit, an input unit, a target chamber, a proton-radiating unit and a storage unit. The pressure-controlling unit includes a first regulating valve, a second regulating valve connected to the first regulating valve and a third regulating valve connected to the first regulating valve. The input unit is connected to the second regulating valve. The target chamber is connected to the third regulating valve and the input unit. The proton-radiating unit is located near the target chamber. The storage unit is connected to the target chamber.

Abstract: A liquid and a gas is constantly filled into a target chamber of a target. Then the liquid and the gas flow around the chamber and are flown out. By doing so, the target is effectively cooled down.

Abstract: A liquid and a gas is constantly filled into a target chamber of a target. Then the liquid and the gas flow around the chamber and are flown out. By doing so, the target is effectively cooled down.